Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level

Journal of the Medical Association of Thailand

Volumn 88, Issue 3, 2005, Pages 399-406

  Tantikosoom, Wirote ^a   Thinkhamrop, Bandit ^a   Kiatchusakul, Songsak ^b   Jarernsiripornkul, Narumol ^a   Srinakarin, Jiraporn ^b   Ojongpian, Siwanit ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Atorvastatin; Endothelial dysfunction; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO;

ADULT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; BRACHIAL ARTERY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; THAILAND; VASCULAR ENDOTHELIUM;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; OUTPATIENTS; PYRROLES; VASCULAR DISEASES;

EID: 20344398940     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Fein F, Scheur J. Heart disease in diabetes mellitus: theory and practice. In: Rifkin H, Porte D Jr, editors. Diabetes mellitus: Theory and Practice. 4th ed. New York: Elsevier, 1990: 812-23.
2. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 1998;21:1138-45.
3. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
4. Chan NN, Colhoun HM, Vallance P. Cardiovascular risk factors as determinants of endothelium-dependent vascular reactivity in the general population. JACC 2001; 38: 1814-20.
5. Najemmik C, sinzinger H, Kritz H. Endothelial dysfunction, atherosclerosis and diabetes. Acta Med Austriaca 1999; 26: 148-53.
6. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and Endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
7. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impair endothelium dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-6.
8. Cohen RA. Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993; 87 Suppl V: v67-76.
9. Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cell in culture, delayed replication, disturbed cell cycle and accelerated death. Diabetes 1985; 34: 621-7.
10. Yasue H, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of achetylcholine by age and segment: Possible role of early coronary atherosclerosis. Circulation 1990; 81: 482-90.
11. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors far coronary artery disease. Circulation 1990; 81: 491-7.
12. Liao JK, Bettmarm Ma, Sander T, tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991; 68: 1027-34.
13. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-74.
14. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998; 82: 1535-9.
15. Neunteufel T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111-8.
16. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long term follow up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
17. Schachinger V, Britten M, Zeiher A. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
18. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetic Care 1997; 20: 614-20.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996; 335: 1001-9.
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol level: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
21. Treasure CB, Klein JC, Weistraub WS, Talley JD, Still A, Bower ME, et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
22. Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effect of acute hypercholesterolemia: Reversal with lovastatin treatment. J Clin Invest 1989; 83: 465-73.
23. Vogel RA, Coretti MC, Gellmen J. Cholesterol, cholesterol lowering, and endothelial function. Progress in Cardiovascular Diseases 1998; 41: 117-36.
24. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
25. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. AHA Scientific statement: Diabetes and Cardiovascular Disease, A statement for Healthcare Professionals from the American Heart Association. Circulation 1999; 100: 1134-46.
26. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statin, implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
27. Laufs U, La Fata V, Plutzky J. Upregulation of endothelial nitric oxide synthase by HMG CoA. Reductase inhibitors. Circulation 1998; 97: 1129-35.
28. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits LDL oxidation and alters its fluidity and uptake by macrophages: in vitro in vivo studies. Metabolism 1992; 41: 229-35.
29. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, et al. Effect of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196-201.
30. Rosenson RS. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225-32.
31. Scechter M, Sharir M, Paul Labrador MJ, Forester J. Improvement in endothelium dependent brachial artery flow mediated vasodilation with low density lipoprotein cholesterol level < 100 mg/dl. Am J Cardiol 2000; 86: 1256-9.
32. Wassmann S, Ribaudo N, Faul A, Laufs U, Nickenig G. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol level < 130mg/dL. Am J Cardiol 2004; 93: 84-8.
33. Sheu WH, Juang BL, Chen YT, Lee WJ. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 1999; 22: 1224-5.
34. van Venrooij FV, van de Ree MA, Bots ML, Stock RP, Huisman MV, Banga JD. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes. Diabetes Care 2002; 25: 1211-6.
35. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH. Atorvastatin lower C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 563-8.
36. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumaru T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000; 404: 787-90.
37. Cosentino F, Hishikawa K, Katusis ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1998; 97: 1695-701.